Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
June 21, 2024 07:00 ET
|
Arvinas Inc.
– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – – Preclinical data presented at the...
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 17, 2024 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
June 11, 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
AI Brain Health Leader Omniscient Closes Series C Funding Round
June 11, 2024 11:00 ET
|
Omniscient Neurotechnology
Omniscient secures Series C funding to expand Quicktome® platform, advancing connectomics for improved brain health diagnostics and treatments.
Arvinas to Participate in Upcoming Investor Conferences
June 03, 2024 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Precision Neuroscience Announces World Record for Number of Electrodes Placed On Human Brain
May 28, 2024 09:00 ET
|
Precision Neuroscience
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation (Precision) and a neurosurgery team from the Mount Sinai Health System now hold the...
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
May 28, 2024 08:00 ET
|
Neurona Therapeutics
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
Precision Neuroscience Expands Clinical Research In Brain–Computer Interface
March 22, 2024 08:30 ET
|
Precision Neuroscience
NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at...
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
March 07, 2024 07:00 ET
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
February 27, 2024 08:00 ET
|
Healis Therapeutics
CKDB-501A, a novel BoNT/A neuromodulator protein, completed a Phase 3 trial to investigate the efficacy and safety in treating the glabella.